Acute Leukemias - Republican Scientific Medical Library
Acute Leukemias - Republican Scientific Medical Library
Acute Leukemias - Republican Scientific Medical Library
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
260 Chapter 20 · Minimal Residual Disease Studies in <strong>Acute</strong> Lymphoblastic Leukemia<br />
33. Foa R, et al. (2003) E2A-PBX1fusion in adult acute lymphoblastic<br />
leukaemia: Biological and clinical features. Br J Haematol 120(3):<br />
484–487<br />
34. Romana SP, et al. (1995) High frequency of t(12;21) in childhood Blineage<br />
acute lymphoblastic leukemia. Blood 86(11):4263–4269<br />
35. Shurtleff SA, et al. (1995) TEL/AML1fusion resulting from a cryptic<br />
t(12;21) is the most common genetic lesion in pediatric ALL and<br />
defines a subgroup of patients with an excellent prognosis. Leukemia<br />
9(12):1985–1989<br />
36. Raynaud S, et al. (1996) The 12;21 translocation involving TEL and<br />
deletion of the other TEL allele: Two frequently associated alterations<br />
found in childhood acute lymphoblastic leukemia. Blood<br />
87(7):2891–2899<br />
37. Borkhardt A, et al. (1997) Incidence and clinical relevance of TEL/<br />
AML1 fusion genes in children with acute lymphoblastic leukemia<br />
enrolled in the German and Italian multicenter therapy trials. Associazione<br />
Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster<br />
Study Group. Blood 90(2):571–577<br />
38. de Haas V, et al. (2002) The TEL-AML1 real-time quantitative polymerase<br />
chain reaction (PCR) might replace the antigen receptorbased<br />
genomic PCR in clinical minimal residual disease studies in<br />
children with acute lymphoblastic leukaemia. Br J Haematol<br />
116(1):87–93<br />
39. Pine SR, et al. (2003) Real-time quantitative PCR: Standardized detection<br />
of minimal residual disease in pediatric acute lymphoblastic<br />
leukemia. Polymerase chain reaction. J Pediatr Hematol Oncol<br />
25(2):103–108<br />
40. Sykes PJ, et al. (1992) Quantitation of targets for PCR by use of<br />
limiting dilution. Biotechniques 13(3):444–449<br />
41. Cave H, et al. (1994) Prospective monitoring and quantitation of<br />
residual blasts in childhood acute lymphoblastic leukemia by<br />
polymerase chain reaction study of delta and gamma T-cell receptor<br />
genes. Blood 83(7):1892–1902<br />
42. Ouspenskaia MV, et al. (1995) Accurate quantitation of residual Bprecursor<br />
acute lymphoblastic leukemia by limiting dilution and a<br />
PCR-based detection system: A description of the method and the<br />
principles involved. Leukemia 9(2):321–328<br />
43. Pallisgaard N, et al. (1999) Rapid and sensitive minimal residual<br />
disease detection in acute leukemia by quantitative real-time<br />
RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript. Genes<br />
Chromosomes Cancer 26(4):355–365<br />
44. Chen X, et al. (2001) Quantification of minimal residual disease in<br />
T-lineage acute lymphoblastic leukemia with the TAL-1 deletion<br />
using a standardized real-time PCR assay. Leukemia 15(1):166–170<br />
45. Pongers-Willemse MJ, et al. (1998) Real-time quantitative PCR for<br />
the detection of minimal residual disease in acute lymphoblastic<br />
leukemia using junctional region specific TaqMan probes. Leukemia<br />
12(12):2006–2014<br />
46. Gabert J, et al. (2003) Standardization and quality control studies<br />
of “real-time” quantitative reverse transcriptase polymerase chain<br />
reaction of fusion gene transcripts for residual disease detection<br />
in leukemia – A Europe Against Cancer program. Leukemia 17(12):<br />
2318–2357<br />
47. Donovan JW, et al. (2000) Immunoglobulin heavy-chain consensus<br />
probes for real-time PCR quantification of residual disease<br />
in acute lymphoblastic leukemia. Blood 95(8):2651–2658<br />
48. Bruggemann M, et al. (2000) Improved assessment of minimal residual<br />
disease in B cell malignancies using fluorogenic consensus<br />
probes for real-time quantitative PCR. Leukemia 14(8):1419–1425<br />
49. van der Velden VH, et al. (2002) Immunoglobulin kappa deleting<br />
element rearrangements in precursor-B acute lymphoblastic leukemia<br />
are stable targets for detection of minimal residual disease<br />
by real-time quantitative PCR. Leukemia 16(5):928–936<br />
50. Beishuizen A, et al. (1994) Analysis of Ig and T-cell receptor genes<br />
in 40 childhood acute lymphoblastic leukemias at diagnosis and<br />
subsequent relapse: Implications for the detection of minimal residual<br />
disease by polymerase chain reaction analysis. Blood<br />
83(8):2238–2247<br />
51. Coustan-Smith E, et al. (2002) Use of peripheral blood instead of<br />
bone marrow to monitor residual disease in children with acute<br />
lymphoblastic leukemia. Blood 100(7):2399–2402<br />
52. Griesinger F, et al. (1999) Leukaemia-associated immunophenotypes<br />
(LAIP) are observed in 90% of adult and childhood acute<br />
lymphoblastic leukaemia: Detection in remission marrow predicts<br />
outcome. Br J Haematol 105(1):241–255<br />
53. Dworzak MN, et al. (2002) Prognostic significance and modalities<br />
of flow cytometric minimal residual disease detection in<br />
childhood acute lymphoblastic leukemia. Blood 99(6):1952–<br />
1958<br />
54. Farahat N, et al. (1998) Detection of minimal residual disease in Blineage<br />
acute lymphoblastic leukaemia by quantitative flow cytometry.<br />
Br J Haematol 101(1):158–164<br />
55. Coustan-Smith E, et al. (2000) Clinical importance of minimal residual<br />
disease in childhood acute lymphoblastic leukemia. Blood<br />
96(8):2691–2696<br />
56. Ciudad J, et al. (1998) Prognostic value of immunophenotypic detection<br />
of minimal residual disease in acute lymphoblastic leukemia.<br />
J Clin Oncol 16(12):3774–3781<br />
57. Borowitz MJ, et al. (2003) Minimal residual disease detection in<br />
childhood precursor-B-cell acute lymphoblastic leukemia: Relation<br />
to other risk factors. A Children’s Oncology Group study. Leukemia<br />
17(8):1566–1572<br />
58. Dworzak MN, et al. (2000) Detection of residual disease in pediatric<br />
B-cell precursor acute lymphoblastic leukemia by comparative<br />
phenotype mapping: Method and significance. Leuk Lymphoma<br />
38(3–4):295–308<br />
59. Cave H, et al. (1998) Clinical significance of minimal residual disease<br />
in childhood acute lymphoblastic leukemia. European Organization<br />
for Research and Treatment of Cancer7Childhood Leukemia<br />
Cooperative Group. N Engl J Med 339(9):591–598<br />
60. Roberts WM, et al. (1997) Measurement of residual leukemia during<br />
remission in childhood acute lymphoblastic leukemia. N Engl J<br />
Med 336(5):317–323<br />
61. van Dongen JJ, et al. (1998) Prognostic value of minimal residual<br />
disease in acute lymphoblastic leukaemia in childhood. Lancet<br />
352(9142):1731–1738<br />
62. Goulden NJ, et al. (1998) Minimal residual disease analysis for the<br />
prediction of relapse in children with standard-risk acute lymphoblastic<br />
leukaemia. Br J Haematol 100(1):235–244<br />
63. Brisco MJ, et al. (1994) Outcome prediction in childhood acute<br />
lymphoblastic leukaemia by molecular quantification of residual<br />
disease at the end of induction. Lancet 343(8891):196–200<br />
64. Foroni L, et al. (1997) Molecular detection of minimal residual<br />
disease in adult and childhood acute lymphoblastic leukaemia